• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 5, 2016

View Archived Issues

No forward 'Momenta' for necuparanib as phase II trial enrollment halted

Momenta Pharmaceuticals Inc. heeded the recommendation of an independent data safety monitoring board (DSMB) and stopped enrollment in the phase II trial of necuparanib (M402) in patients with advanced metastatic pancreatic cancer following the trial's planned interim futility analysis. Read More

Zika vaccine trials off and running – for now

A week after Inovio Pharmaceuticals Inc. began testing its Zika vaccine, GLS-5700, in healthy volunteers, the National Institutes of Allergy and Infectious Diseases (NIAID) announced on Tuesday it has dosed the first patient in the phase I VRC 319 trial of its own Zika vaccine. Read More

Zika diagnostics take center stage as battle against virus moves inside U.S. border

In a historic move, the CDC has issued a warning for those living in or traveling to a Miami neighborhood after the Zika virus was detected and spreading. Included in that warning is a recommendation that pregnant women be tested for the virus. How have diagnostics players stepped up to protect this – and other – vulnerable populations? Read More

NIH, BARDA to spend through Zika funding by end of the month

When Congress returns to Washington Sept. 6 following its August recess, lawmakers will face two looming deadlines – for passage of fiscal 2017 spending authorizations and more funding to battle the Zika virus. Read More

Adaptive pathways program to continue after EMA's 2-year pilot

LONDON – It's so far, so good for adaptive pathways, with the EMA's final report on its pilot scheme concluding that staggered approval from a small patient subgroup to an increasingly wide patient population can support development in indications where it is hard to generate sufficient data, but that new methodologies are required for gathering data once products are on the market. Read More

Financings

Cesca Therapeutics Inc., of Rancho Cordova, Calif., entered subscription agreements with institutional investors for a registered direct offering of 600,000 common shares at $4.10 apiece, a 24 percent discount to the closing price of $5.42 for the company's shares (NASDAQ:KOOL) on Aug. 3. Read More

Other news to note

Trevena Inc., of King of Prussia, Pa., disclosed in its second-quarter earnings that Dublin-based Allergan plc notified the company this month that it does not plan to exercise its exclusive option to license G protein-coupled receptor candidate TRV027. Read More

In the clinic

Adaptimmune Therapeutics plc, of Oxford, U.K., said it received FDA notice of a partial clinical hold on its planned pivotal study of NY-ESO SPEAR T-cell therapy in myxoid round cell liposarcoma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe